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Abstract 1	
T1D is an autoimmune disease characterized by T cell-mediated destruction of 2	
insulin-producing β-cells in the pancreatic islets of Langerhans, resulting in 3	
hyperglycemia, with patients requiring lifelong insulin treatment.  Many studies have 4	
shown that genetics alone are not sufficient for the increase in T1D incidence and thus 5	
other factors have been suggested to modify the disease risk.  T1D incidence has sharply 6	
increased in the developed world, especially amongst youth1.  In Europe, T1D incidence 7	
is increasing at an annual rate of 3-4%2.  Increasing evidence shows that gut microbiota, 8	
as one of the environmental factors influencing diabetes development, play an important 9	
role in development of T1D3.  Here, we summarize the current knowledge about the 10	
relationship between the microbiota and T1D.  We also discuss the possibility of T1D 11	
prevention by changing the composition of gut microbiota.  12	
 13	
Introduction 14	
 The elucidation of the complex interactions between the gut microbiota, 15	
metabolism, and the immune system may lead to groundbreaking changes as to how 16	
specific diseases are prevented and treated.  The gut microbiota refers to the community 17	
of bacteria located within the intestine that have coevolved through millions of years with 18	
the host.  This symbiotic relationship is important for many host functions including 19	
digestion, nutrient acquisition, and the development of the immune system4.  20	
The gut microbiota encodes trillions of genes, of which approximately 5-10 21	
million are unique5-7.  In total, there are ~150 times more genes than in the human 22	
genome6.  In healthy humans, the number of the bacteria increases exponentially from the 23	
small intestine to the colon; thus, the colon is the main contributor to the total bacterial 24	
population in the gut8.  The main commensal bacterial phlya in the gut microbiota 25	
include, Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, and Verrucomicrobia 26	
with the vast majority consisting of Bacteroidetes and Firmicutes. 27	
The gut microbiota of each individual host is diverse and unique9.  For 28	
maintenance of good health, there is a natural balance between the host and its microbial 29	
community.  However, dysbiosis, which is a disturbance in the balance between the host 30	
and the microbial community, is associated with various chronic diseases, including 31	
	 3	
obesity, inflammatory bowel disease (IBD), type 1 diabetes (T1D) and type 2 diabetes 1	
(T2D)10. 2	
 Recent evidence suggests the gut microbiota may begin colonization in utero as 3	
bacteria have been detected in the intrauterine environment including the amniotic fluid11, 4	
placenta12, meconium13, and the umbilical cord14.  While the majority of these studies 5	
utilize 16S rRNA sequencing or PCR, in a small number the investigators have grown 6	
bacteria by culturing the amniotic fluid11 or the umbilical cord14 samples in different 7	
bacterial culture conditions.  In addition, the development of the gut microbiota can be 8	
influenced by the delivery mode.  Infants delivered by Caesarean section (C-section) 9	
exhibit less bacterial diversity up to 2 years after birth compared with those delivered 10	
vaginally15.  C-section deliveries have also been associated with an increased risk of 11	
obesity16 or T1D17 later in life, which may be linked to the fact that the gut microbiota 12	
continue to develop into adulthood18.  This potentially provides a greater window of 13	
opportunity for therapeutic modulation of the gut microbiota. 14	
There are many ways that the gut microbiota can be modified, including the 15	
environments we live in (e.g. rural or urban), diet and food supplements (probiotics), the 16	
use of antibiotics or other medications during illness.  Other factors, such as age and 17	
gender, can also modify the microbial composition over time.  For example, the healthy 18	
pediatric gut microbiota exhibit significant compositional and functional differences from 19	
those of adults18.  It has been shown that children had increased abundances of 20	
Bifidobacterium, Faecalibacterium, and Lachnospiraceae compared with adults, while 21	
adults had increased abundance of Bacteroides4.  Currently, it is not clear what 22	
constitutes a “healthy” gut microbial composition; however, the microbiota are 23	
indispensible for the digestion of nutrients19, development of mucosal immunity20, and 24	
supporting gut-brain communication21.  Furthermore, a loss of diversity in the gut 25	
microbiota or alterations in microbial functions have been associated with risk of 26	
developing chronic diseases including T1D and other autoimmune or inflammatory 27	
disorders.  Therefore, developing or retaining a “healthy” microbiota is important. 28	
 T1D is an autoimmune disease characterized by T cell-mediated destruction of 29	
insulin-producing β-cells in the pancreatic islets of Langerhans, resulting in 30	
hyperglycemia, with patients requiring lifelong insulin treatment.  Many studies have 31	
	 4	
shown that genetics alone are not sufficient for the increase in T1D incidence and thus 1	
other factors have been suggested to modify the disease risk.  T1D incidence has sharply 2	
increased in the developed world, especially amongst youth1.  In Europe, T1D incidence 3	
is increasing at an annual rate of 3-4%2.  Increasing evidence shows that gut microbiota, 4	
as one of the environmental factors influencing diabetes development, play an important 5	
role in development of T1D3.  Here, we summarize the current knowledge about the 6	
relationship between the microbiota and T1D.  We also discuss the possibility of T1D 7	
prevention by changing the composition of gut microbiota.  8	
 9	
Animal Models of T1D 10	
 To gain the best knowledge of the mechanism(s) of a disease development, the 11	
ideal studies are in vivo investigations.  For ethical reasons, there are considerable 12	
limitations to in vivo studies in humans.  However, animal models of human diseases 13	
provide an alternative system to investigate the mechanism behind the immune response 14	
within the pancreas, in the case of T1D, or the bacteria in the gut, in vivo, to answer 15	
questions that we cannot do in humans.  Utilizing bench to bedside and bedside to bench 16	
approaches can further expand our understanding and help us to achieve the ultimate goal 17	
of preventing T1D development or to develop a cure. 18	
 There are two widely used rodent models for human T1D research - the non-19	
obese diabetic (NOD) mouse22 and the bio-breeding (BB) rat23.  Both the NOD mouse 20	
and the BB rat develop spontaneous T1D, similar to humans.  NOD mice usually develop 21	
T1D after 10 weeks of age24, while BB rats develop T1D from 7 to 14 weeks25.  In 22	
affected humans, the age of onset of T1D typically ranges from 6 months to late 23	
adolescence.  The NOD mouse and the BB rat also carry the T1D susceptibility major 24	
histocompatibility complex (MHC) class II genes, similar to the human T1D 25	
susceptibility MHCII alleles.  The NOD mouse recapitulates many features of human 26	
T1D, especially those T1D susceptibility genes26.  However, the pathogenesis of T1D in 27	
both humans and animal models is not solely determined by genetics; the disease onset is 28	
influenced by a combination of genetic and environmental factors.  Pathologically, 29	
humans27, the BB rat28 and NOD mice29 display infiltration of lymphocytes in the 30	
pancreas, namely, insulitis.  The immune cells that are involved in the destruction of 31	
	 5	
insulin-producing beta cells in humans, are similar to those cells present in NOD mice 1	
and BB rats during diabetes development.  These cells are mainly autoreactive T cells as 2	
T1D is a T cell-mediated disease.  Furthermore, the autoantigens that the T cell 3	
recognizes in human T1D are also present in the NOD mouse30.  In humans, a gender bias 4	
emerges after puberty with a small increase in the number of affected males31, while the 5	
majority of diabetic NOD mice are females22.  However, there is no gender bias in T1D 6	
development in BB rats23. 7	
 Unlike human studies, studies using animal models can be better controlled in 8	
order to minimize variables and assess the effect of different environmental factors, such 9	
as diet, mode of birth delivery and usage of medication, on the gut microbiota and the 10	
development of T1D.  Therefore, studies using animal models provide an extremely 11	
valuable and unique tool for gaining more insightful knowledge about the disease.  In 12	
addition, humans32 and rodents33, 34 with T1D have been shown to exhibit similar 13	
gastroenterological abnormalities, including increased intestinal permeability, altered 14	
microvilli, leaky tight junctions, and altered gut microbiota35-37.  Similar to humans, 15	
Bacteroidetes and Firmicutes are also the dominant phyla in relation to the composition 16	
of gut microbiota.  However, there are also major differences as 85% of the bacterial 17	
genera found in mice are absent in humans38.  Moreover, a disadvantage of well-18	
controlled studies using in-bred animal models may be a lack of direct translation to 19	
humans, who are extremely heterogeneous. 20	
 21	
Gut Microbiota and T1D 22	
 23	
Hygiene Hypothesis 24	
The concept of the gut microbiota as a major environmental factor influencing 25	
T1D supports the rising incidence rates in developed countries.  The hygiene hypothesis 26	
originally was coined in relation to observations of respiratory problems, hygiene and 27	
household size39.  A modification of this may help to explain the increased T1D 28	
incidence as a result of reduced diversity in the microbiota.  The sharp increase in T1D 29	
incidence dates back to the mid 20th century where children were raised in environments 30	
with increased levels of sanitation and thus have less exposure to bacteria and parasites.  31	
	 6	
The hygiene hypothesis has been tested in NOD mice, as the cleaner the living 1	
conditions, the higher the incidence of diabetes found in NOD mice40.  Moreover, studies 2	
have found that infection of NOD mice early in life with a number of different bacteria 3	
can prevent T1D41, 42.  Human epidemiological studies showed that the incidence of T1D 4	
and allergies is much lower in developing countries where the living standard is low but 5	
the rate of bacterial or parasite infection is high43.  Links found between gut microbiota 6	
and T1D, discussed in this review, have prompted questions on how the gut microbiota 7	
can be modulated in order to alter T1D development.  8	
 9	
Gut Microbiota in T1D 10	
Both the gut microbiota composition and the immune system co-evolve and 11	
develop together over time, and young children have reduced microbial diversity and a 12	
less mature immune system compared to adults18, 44.  Therefore, it is important to 13	
understand how the gut microbiota interacts with the immune system and further, how 14	
these interactions alter susceptibility to T1D.  Roesch and colleagues found that bacteria 15	
of the Bacteroides genus were more common in diabetes-prone BB rats (BB-DP) than 16	
they were in diabetes-resistant BB rats (BB-DR)45.  However, the abundance of bacteria 17	
belonging to the Lactobacillus and Bifidobacterium genera was higher in BB-DR rats 18	
than in BB-DP rats45.  Altered microbiota were also found between the NOD mouse and 19	
non-obese diabetes resistant (NOR) mouse46.  According to Daft and colleagues, the 20	
NOD mouse has a lower Firmicutes:Bacteroidetes ratio as well as a lower abundance of 21	
Prevotella compared to the NOR mouse46.  This profile is also seen in children with T1D 22	
compared to age-matched healthy children37.  Long-term changes in the gut microbiota of 23	
NOD or NOR mice can be accomplished by cross-fostering, whereby NOD mice are 24	
nursed by NOR mothers and vice versa46.  Cross-fostering of NOD mice results in both 25	
the loss of some diabetogenic bacteria and the gain of bacteria associated with diabetes 26	
protection.  Further, NOD mice fostered by NOR mothers had a decreased incidence of 27	
T1D46.   28	
Gut microbiota can modulate T1D susceptibility associated with known T1D 29	
susceptibility loci.  Genetic susceptibility at the MHC loci is the most important risk 30	
factor for T1D development in both NOD mice and humans.  NOD mice express the gene 31	
	 7	
encoding MHC class II IAg7, which is a homolog of human HLA-DQ847-49.  NOD mice 1	
do not express IE, another MHC class II gene, a homolog of human HLA-DR48, 49.  2	
Expression of IE, or expression of IAb, the MHC class II locus for C57BL/6 mice, instead 3	
of IAg7, is associated with protection from disease in NOD mice50, 51.  Interestingly, a 4	
recent study by Silverman et al. suggested the mechanism of disease protection is 5	
mediated by gut microbiota in IE-expressing NOD mice52.   The authors showed that 6	
expression of the IE transgene results in the compositional changes in gut microbiota 7	
which contributes to T1D protection.  To prove that the disease protection was indeed 8	
mediated by the gut microbiota, the authors treated the IE transgenic NOD mice with 9	
different antibiotics.  Administration of vancomycin or metronidazole, but not neomycin 10	
or ampicillin, in the drinking water, disturbed the gut microbiota sufficiently to induce 11	
insulitis in the normally insulitis-free IE transgenic NOD mice52.  However, although the 12	
presence of IAb in NOD mice was also able to alter the gut microbiota composition, the 13	
effect on diabetes development was minimal53.  Expression of other T1D protective 14	
genetic loci Idd3 and/or Idd5 from C57BL/6 mice in NOD mice54, 55 did not lead to 15	
changes in gut microbiota but enhanced IL-2 production and Treg function.  Mullaney 16	
and co-authors further assessed the microbiota from healthy humans carrying the Idd3/5 17	
protective alleles and found similar gut microbiota composition to NOD mice expressing 18	
the same alleles53.  These studies not only support the importance of the NOD mouse 19	
model of human T1D, but also reveal the importance of the genetic susceptibility loci in 20	
T1D, which modulate the interactions of immune cells and gut microbiota.  21	
Alterations in the gut microbiota have also been observed in humans with T1D.  22	
A study by Giongo and colleagues analyzed bacteria in fecal samples of infants and 23	
young children and discovered that children who developed T1D had higher proportions 24	
of bacteria from the Firmicutes phylum and lower proportions of bacteria in the 25	
Bacteroidetes phylum than age-matched healthy controls at 4-8 months of age37.  26	
However, by the age of 2, children who had developed T1D had a higher proportion of 27	
Bacteroidetes and a lower proportion of Firmicutes relative to healthy controls56.  Rather 28	
than using stool samples, one study compared the duodenal gut microbiota of patients 29	
with T1D, or those with celiac disease (CD) and with that of the healthy control 30	
subjects32 (due to proximity of the duodenum and close relationship to the pancreas).  31	
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Some patients with T1D in the study had a gastroduodenal endoscopy and biopsy for CD 1	
diagnostic purposes.  However, the authors found a distinctive inflammatory profile in 2	
the patients with T1D32.  Patients with T1D showed overexpression of ten inflammation-3	
associated genes in the biopsies, including chemokines and TNFα, compared to both 4	
healthy controls and CD patients32.  Further, only patients with T1D exhibited an 5	
increased Firmicutes and Firmicutes/Bacteroidetes ratio but reduced proportion of 6	
Proteobacteria compared to either patients with CD or healthy controls32.   7	
In addition, some studies have investigated the gut microbiota in individuals who 8	
are positive for islet autoantibodies and those who are not.  In a US-based study, the gut 9	
microbiota composition was found to be different between seropositive individuals and 10	
their seronegative first-degree relatives (FDRs) with an increased abundance of 11	
Catenibacterium, Prevotellaceae and RC9 gut group bacteria in the former57.  12	
Interestingly, the authors also found that the overall composition of gut microbiota in 13	
autoantibody-positive individuals and seronegative FDRs were similar but different from 14	
those recent-onset T1D patients and unrelated healthy controls57.  It is not clear if the 15	
FDRs were living in the same or a similar environment; however, this suggests some 16	
genetic influence in the composition of gut microbiota and changes in the gut microbiota 17	
prior to and/or soon after T1D development.  In a European study, Endesfelder and 18	
coauthors also compared the compostion of gut microbiota between seropositive or 19	
seronegative individuals who have an FDR with T1D58.  Their results did not reveal any 20	
differences between autoantibody-positive and -negative individuals in microbiota 21	
diversity and composition, as well as single-genus abundance58.  However, the authors 22	
found substantial changes in microbial interaction networks, especially in young children 23	
who later developed autoantibodies58.  In another study, the microbiota composition and 24	
alpha diversity in European children, who had seroconverted and later developed 25	
diabetes, was different to those who did not seroconvert56.  In addition, the children who 26	
seroconverted but had not developed diabetes by 3 years of age, had a microbiota 27	
composition and alpha diversity more similar to non-seroconverters.  Together, the data 28	
confirmed microbial changes prior to and post-diabetes development.  While most studies 29	
have focused on 16S rRNA sequencing of the microbiota, Pinto and colleagues 30	
investigated the microbial proteome, i.e. the proteins expressed by microbiota isolated 31	
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from stool samples of healthy children and children with T1D59.  The authors found that 1	
children with T1D had a higher abundance of proteins from Clostridia and Bacteroidetes, 2	
while healthy children had a higher proportion of proteins from Bifidobacterium.  3	
Although many studies provide evidence of altered gut microbiota in individuals with 4	
T1D compared to healthy control subjects, few have shown a causal link between the 5	
altered gut microbiota and the disease.   However, it is important to note that some of the 6	
human studies had very small group sizes, with as few as 3-4 individuals/group37, 59.  7	
Thus, larger studies are needed.  However, the data from the current human studies 8	
suggest that the altered microbiota and their interactions with the immune system are 9	
likely to contribute to T1D susceptibility.  Therefore, it is important to do functional 10	
studies in vivo and animal models can provide the perfect tools for this purpose.   11	
 12	
Pattern Recognition Receptors 13	
Pattern recognition receptors (PRRs) are germ-line encoded and thus have been 14	
conserved over thousands of years to bind conserved structures from pathogens, 15	
designated as pathogen-associated molecular patterns (PAMPs), which are present in 16	
microorganisms60.  An example of a PAMP is lipopolysaccharide (LPS), a major 17	
component of the outer membrane of gram-negative bacteria61.  There are several PRR 18	
families including Toll-like receptors (TLRs) and nucleotide-binding oligomerization 19	
domain-like receptors (NLRs).   20	
 21	
TLRs 22	
At least 10 and 13 members of the TLR family have been identified in human and 23	
mouse, respectively, all of which recognize different PAMPs62.  TLRs are expressed 24	
either on the cell surface (TLR1, 2, 4, 5, 6, 10, 11 and 12) or within the cells (TLR3, 7, 8, 25	
9 and 13).  TLRs function via signaling through the activation of the NF-κB signaling 26	
pathway, inducing proinflammatory cytokines that enable the innate immune system to 27	
quickly eradicate potential microbial threats. 28	
There are two major TLR signaling pathways mediated by different adaptor 29	
proteins, the Myeloid differentiation primary response gene 88 (MyD88) and the Tir-30	
domain-containing adaptor-inducing interferon β protein (TRIF).  TLR3, a receptor for 31	
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double stranded RNA, relies solely on TRIF signaling, while TLR4, a receptor for LPS, 1	
can signal through both MyD88 and TRIF; all the other TLRs rely on MyD8863-65.  2	
Antigen presenting cells (APCs) express many TLRs and play an important role in 3	
linking gut microbiota and the host immune system66. TLR signaling is essential because 4	
it enables optimal antigen presentation by inducing APC maturation and costimulation, as 5	
well as the release of cytokines61, 65, 67-69. 6	
 TLR interactions with the gut microbiota have been found to be important in 7	
contributing to T1D susceptibility.  MyD88-deficient (MyD88-/-) NOD mice are 8	
completely protected from diabetes under normal, specific-pathogen free (SPF) 9	
conditions, where gut microbiota are present70.  However, diabetes was partially restored 10	
in the MyD88-/-NOD mice after antibiotic administration, suggestive of microbial 11	
involvement in the protection of the mice.  Interestingly, re-deriving the MyD88-/-NOD 12	
mice to germ-free (GF) conditions abolished the disease protection.  Introduction of 13	
commensal bacteria to the GF MyD88-/-NOD mice markedly reduced diabetes 14	
development.  These results demonstrate that MyD88-dependent signaling is important 15	
for T1D development, which can be modulated by gut microbiota.  Burrows and 16	
colleagues reported that diabetes susceptibility in TLR4-/-NOD mice and protection in 17	
TLR2-/-NOD mice were also modulated by gut microbiota71.  LPS recognition has 18	
recently drawn more attention in the T1D research field.  It is known that Finland has the 19	
highest T1D prevalence worldwide, whereas the incidence of T1D in Russia Karelia, a 20	
close neighbor of Finland, is six times lower72.  In addition, there is a greatly reduced risk 21	
of developing other autoimmune and allergic diseases in Russion Karelia73, 74.  22	
Investigation of the microbiota composition in children living in the different regions 23	
revealed that Finnish children had more Bacteroides species encoding more LPS 24	
synthesis genes, when compared to Russian infants3.  Furthermore, the LPS from the 25	
Bacteroides species isolated from Finnish children was structurally and functionally 26	
different from the LPS of E.coli, a Bacteroides species, found in Russian infants.  When 27	
the immune function of the two different LPS types in NOD mice was tested, the LPS 28	
from Bacteroides isolate of the Finnish children was more immunostimulatory than the 29	
LPS from the E.coli isolate from the Russian children.  The finding suggests that altered 30	
LPS recognition by TLR4 may be important in modulating susceptibility to T1D.  31	
	 11	
Interestingly, TLR3-deficiency on the NOD background had no impact on diabetes 1	
development; however, viral infection models of diabetes development required TLR3 on 2	
both the NOD background as well as other genetic backgrounds for diabetes to develop75-3	
79.  Furthermore, it was noted that enhanced costimulatory molecule expression in the 4	
islets, using transgenic constructs directed by the rat insulin promoter, involved changes 5	
to the gut microbiota and signaling through TLR3 and MyD88 pathways79.  Our studies 6	
also showed that TLR9-deficient NOD mice80 and TRIF-deficient NOD mice81 are 7	
protected from T1D development.  LPS is the ligand of TLR4 and TRIF is one of the two 8	
downstream signaling pathways of TLR4.  It is interesting that diabetes protection in 9	
TRIF-deficient NOD mice is mediated by gut microbiota81.  Taken together, most TLRs 10	
are required for T1D development in NOD mice, while TLR4 signaling regulates the 11	
development of T1D through gut microbiota and/or LPS. 12	
 13	
NLRs 14	
Another family of PRR is the nucleotide-binding oligomerization domain-like 15	
receptors (NLRs).  These NLRs recognize both PAMPs and damage-associated 16	
molecular patterns (DAMPs; molecules produced by stressed cells to promote an 17	
inflammatory response).  One of the best-studied NLRs is the nucleotide-binding 18	
oligomerization domain-containing protein 2 (Nod2). Mutations in this receptor mediate 19	
susceptibility to inflammatory bowel disease in humans82, 83.  We recently showed that 20	
Nod2 also influences T1D development in NOD mice, mediated by altered gut 21	
microbiota84.  In this study, Nod2-/-NOD mice were protected from T1D only when 22	
housed with other Nod2-/-NOD mice.  If the Nod2-/-NOD mice were housed with Nod2-23	
sufficient wild-type NOD mice, the Nod2-/-NOD mice developed a similar T1D incidence 24	
to WT NOD mice.  This provides important evidence that the environmental conditions 25	
e.g. housing status can alter the interpretation of the disease phenotype in genetically 26	
modified mouse strains in T1D studies. 27	
   The nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin 28	
domain-containing 3 (NLRP3) inflammasome is another protein involved in the detection 29	
of pathogens by innate immune cells.  We found reduced expression of chemokines and 30	
chemokine receptors on both pancreatic islets and T cells in NLRP3-/-NOD mice, which 31	
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protected the mice from developing T1D85.  It is currently unknown whether this process 1	
is modulated by the gut microbiota.  The role of other NLR members in mediating T1D 2	
susceptibility is also unknown.   3	
 4	
APC and gut microbiota interactions 5	
Dendritic cells (DCs) 6	
DCs are potent APCs found in both lymphoid and non-lymphoid tissue.  Studies 7	
have shown that DCs are enriched at mucosal sites86, 87 and can sample microbial 8	
antigens from the gut lumen, presenting the antigens to the T cells and possibly B cells, 9	
residing in the mucosal tissue88, 89.  Mucosal DCs express a number of chemokine 10	
receptors and tissue homing adhesion molecules including CD103, all of which facilitate 11	
the intestinal DCs to migrate to other tissue sites after antigen uptake from the gut 12	
lumen90, 91.  DCs express a range of PRRs, and signaling through these induces 13	
maturation, promotes survival and maintains homeostasis within the DCs69, 92-98.  Thus, 14	
DCs are a pivotal component of the immune system, linking innate and adaptive 15	
immunity and inducing a specific immune response to pathogens but also to self-antigens 16	
in the context of autoimmunity.   17	
In T1D, DCs present self-antigen and activate autoreactive T cells which damage 18	
and destroy pancreatic β-cells99.  DC activation through TLR9 and/or TLR3 has been 19	
shown to be important in enhancing IFNα secretion and thus promoting T cell activation 20	
and T1D development in NOD mice and humans100, 101.  Turley and colleagues have also 21	
shown that pancreatic draining lymph nodes (PLNs) function as an intersection for 22	
immune responses to gut non-self antigen and pancreatic self-antigen102.  It is 23	
conceivable that some microbial antigens may share antigenic homology with pancreatic 24	
self-antigen, which can be sampled by intestinal DCs and promote undesirable 25	
autoimmune responses.  In this regard, we have recently shown that autoreactive and 26	
diabetogenic CD8 T cells recognize a microbial peptide and promote the acceleration of 27	
T1D development in a T cell receptor (TCR) transgenic NOD mouse103. 28	
 29	
B cells 30	
	 13	
 B cells originate and develop in the bone marrow.  Mature B cells can 1	
differentiate to antibody-secreting plasma cells.  IgM is the first antibody that B cells 2	
produce in response to pathogen invasion. However, IgM is usually low affinity and 3	
hence the need for affinity maturation including class switching, i.e., Ig gene 4	
rearrangements, to generate antibodies with high affinity, in order to more specifically 5	
target the antigen and control pathogen invasion104-106.  B cells undergo class switching in 6	
response to different antigens.  The type of class-switched antibody produced by B cells 7	
is also determined by the tissue location.  For example, IgA is the predominant antibody 8	
in the mucosal tissues, while IgG is the most prevalent antibody in the circulation107.  B 9	
cells often require T cell help to complete class switching; however, commensal bacteria 10	
and/or bacterial antigens presented by mucosal DCs can induce B cells to secrete IgA, 11	
which protects the mucosa from invasion by pathogens and reduces inflammatory 12	
signals108, 109.  Intestinal epithelial cells can also induce IgA secretion110.  13	
In addition to antibody secretion, B cells also function as antigen presenting cells, 14	
promoting diabetes development111-113.  Although T1D is considered a T-cell mediated 15	
disease, it has become clear that B cells play an important role in the development of 16	
T1D.  The precise role of B cells in the pathogenesis of T1D is complex and not fully 17	
understood; however, the autoantibodies produced by self-reactive B cells provide a very 18	
good biomarker to predict T1D onset in the individuals with high risk of developing T1D.  19	
The self-reactive B cells in T1D produce IgG autoantibodies to a range of antigens 20	
including insulin114, GAD115, IA-2116 and ZnT8117.  Less is known about the role of IgA 21	
in T1D, although data from two T1D studies provide conflicting evidence as to whether 22	
the IgA concentrations in the serum are different between controls and T1D patients118, 23	
119.  IgA is enriched in mucosal sites of both mouse and human in a secretory form and it 24	
is estimated that approximately 40 mg/kg body weight of IgA are produced in human 25	
intestine120, 121.  Detection of immunoglobulins bound to the bacteria within the 26	
intestine122, 123 may provide new avenues of investigation for T1D studies, enabling us to 27	
understand which gut microbiota become antibody targets and how the immune system 28	
interacts with them.  29	
B cells in NOD mice express enhanced levels of some PRRs (and associated 30	
molecules) compared to C57BL/6 mice124.  Further, unmethylated CpG 31	
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deoxyoligonucleotides, which are a ligand for TLR9, activated pro-B cells.  These cells 1	
have a regulatory function and are capable of protecting NOD mice from T1D 2	
development125.  Interestingly, the C1858T (lyp) polymorphism of the PTPN22 gene in 3	
humans was also associated with altered B cell responses in individuals with T1D after 4	
stimulation with CpG126.  Therefore, innate signals can mediate important changes 5	
altering susceptibility to T1D in both NOD mice and humans.  However, B cells are not 6	
the only adaptive immune cells to be influenced by the gut microbiota. 7	
 8	
T Cells are influenced by gut microbiota  9	
T cells are a major player in the adaptive immune responses that both fight against 10	
pathogens and regulate immune responses to maintain immuno-homeostasis.  T cells 11	
originate from bone marrow stem cells and undergo development in the thymus 12	
(including the gene rearrangements that enable the antigen-specific TCR to be 13	
expressed).  Thymic T cells also undergo selection processes, ensuring the deletion of 14	
highly auto-reactive T cells, which prevents autoimmunity.  However, this process is not 15	
complete and may contribute to the development of autoimmune disorders in people who 16	
are susceptible to autoimmunity.  17	
T cells expressing their antigen-specific TCR, can recognize a vast diversity of 18	
antigens, pathogens and non-pathogens, which include self-antigens127.  However, the 19	
antigens recognized by the TCR are presented by APCs through the antigenic peptide-20	
MHC complex.  The APCs express costimulatory molecules and produce cytokines, and 21	
these, together with the recognition of specific antigen, stimulate T cells to differentiate 22	
into different effector subsets.  Studies have shown that commensal bacteria, most likely 23	
mediated by APCs, can induce T helper (Th) 1128, 129, Th2130, 131, Th17132, 133 and T 24	
follicular helper (Tfh) cells134.  For example, the presence of Segmented Filamentous 25	
bacteria (SFB) in the gut can induce IL17-producing CD4+ Th17 cells 132, 133, and Tfh 26	
cells134.  Targeting SFB specifically may enable potential treatments for Th17-driven 27	
autoimmune diseases e.g. Experimental Autoimmune Encephalomyelitis (EAE, a mouse 28	
model of multiple sclerosis) and collagen-induced arthritis in mice135, 136.  Although, T1D 29	
is driven by Th1 cells, SFB have been shown to protect NOD mice from T1D when 30	
housed in SPF conditions137. However, SFB introduction into GF NOD mice had no 31	
	 15	
effect on T1D development in female mice, whereas there was a significant delay in T1D 1	
onset in male GF mice after introducing SFB138.  Other studies have shown the inter-2	
regulatory relationship between Th1 and Th17, where Th17 cells are also controlled by 3	
Treg cells.  It is plausible that the Th1/Th17/Treg axis plays an important role in 4	
modulating T1D susceptibility by alteration of gut microbiota.  The newly-identified role 5	
of SFB in altering Tfh differentiation and trafficking in a mouse model of arthritis is 6	
interesting134.  This provides evidence of the microbiota altering T:B cell interactions 7	
within the germinal centers prior to autoimmunity development.  In T1D, Tfh T cells 8	
from diabetic NOD mice can transfer diabetes139 and Tfh cells were found to be increased 9	
in T1D patients140.  A recent study investigating insulin-specific T:B cell interactions in 10	
NOD mice, also revealed an increase in Tfh cells associated with increased diabetes 11	
development141.  Therefore further understanding antigen-specific germinal center 12	
interactions and the influence of gut microbiota, prior to autoimmunity development may 13	
be very important. 14	
 15	
Treg cells  16	
Tregs are characterized by their expression of the forkhead box transcription 17	
factor (FoxP3)142, and are potent at suppressing immune responses143. Tregs were 18	
previously named suppressor T cells144, and we have gained much more understanding of 19	
these cells in recent years.  Tregs can be generated within the thymus (natural Tregs, 20	
nTregs) or in the periphery (induced Treg, iTregs).  FoxP3 deficiency, caused by the 21	
Scurfy x-linked mutation145, resulted in severe immune cell infiltration in multiple organs 22	
and autoimmune destruction146, 147.  Thus, Treg cells are vital in mediating immune 23	
tolerance to autoantigens.  In addition, they are also very important in limiting the 24	
immune response to foreign antigens to prevent tissue damage.  25	
 Tregs, like other immune cells, also express TLRs including TLR4, TLR5, TLR7 26	
and TLR8 as identified by real time PCR148.  Upon LPS stimulation, that is recognized 27	
via TLR4, Tregs became more activated and exhibit enhanced suppressive capabilities148.  28	
Studies have shown that commensal bacteria, such as strains of Clostridium, by 29	
promoting a TGF-β rich environment, induce T effectors to become Tregs in the colon 30	
and protect mice from chemical induced colitis149.  Treg induction was also confirmed in 31	
	 16	
mice given a mixture of human stool-isolated Clostridium species150.  Interestingly, Treg 1	
induction by Clostridium species was independent of PRR signaling, as Treg induction 2	
was not impaired in a number of PRR deficient mice including MyD88-/- mice149.  3	
However, other studies have shown that Treg conversion in colonized germ-free mice 4	
with the altered Schaedler flora (ASF, a mixture of 8 strains of human gut bacteria 5	
including a Clostridium species) is MyD88 dependent151.  It is not clear whether other 6	
strains of bacteria in the ASF also contribute to the Treg conversion.  However, these 7	
studies suggest that Treg induction and the mechanism behind it depend on the type of 8	
bacteria.  More recently, Nod2, a member of the NLR family, which recognizes the 9	
bacterial component muramyl dipeptide (MDP) was also found to regulate human Treg 10	
survival by preventing apoptosis induced by MDP stimulation; however, Tregs from 11	
patients with IBD, who have the Nod2 gene mutation, were not protected from 12	
apoptosis152.  We have shown recently that Nod2-deficient NOD mice are protected from 13	
T1D development, which was, at least in part, mediated by increased gut microbiota-14	
induced Tregs in the pancreatic lymph nodes84.  This data shows the microbiota and 15	
immune recognition together shape the regulatory T cell response and may provide an 16	
important target for therapy.   17	
 18	
Metabolism and the gut microbiota 19	
The intestinal microbiota utilize undigested food products as substrates for 20	
fermentation resulting in the production of different metabolites.  Short-chain fatty acids 21	
(SCFAs), saturated fats, L-carnitine, and choline are examples of microbially-derived 22	
metabolites.  Therefore, the presence of these metabolites depends on the microbiota 23	
composition.  Studies have shown that the metabolites, especially SCFAs influence the 24	
differentiation and function of immune cells; thus, they may play an important role in the 25	
development of T1D. 26	
Other metabolic components including sex hormones can affect the immune 27	
system including the induction of autoimmunity.  The female gender bias in T1D 28	
development seen in the NOD mice has been shown to be consequent upon interactions 29	
between sex hormones and gut microbiota138, 153.  The gut microbiota in male NOD mice 30	
influence the levels of testosterone, and higher levels of testosterone are associated with 31	
	 17	
the protection against T1D development153.  Several human autoimmune disorders have a 1	
strong gender bias, with a higher incidence in women.  While human T1D in adulthood 2	
has a small gender bias towards men, it is important to decipher the role(s) of hormones 3	
and microbiota including microbial products in mediating susceptibility to autoimmune 4	
diseases. 5	
 6	
Metabolites 7	
One of the most significant metabolites produced by gut microbiota are SCFAs, 8	
during the fermentation of dietary fiber in the colon.  Butyrate, propionate, and acetate 9	
are the major SCFAs produced in the gut, which can regulate the host immune system, 10	
central nervous system, gastrointestinal system, and metabolism through various 11	
mechanisms.  The oxidation of SCFAs, butyrate in particular, is the principal energy 12	
source utilized by colonocytes154, 155.  Butyrate also enhances the integrity of human and 13	
mouse intestinal epithelial cells.  This occurs by controlling the assembly of tight 14	
junctions as demonstrated in an in vitro culture system156 and in mice in vivo through the 15	
stabilization of the hypoxia-inducible factor (HIF), a transcription factor important for 16	
mediating epithelial barrier functions157.  Moreover, butyrate can be sensed by the 17	
immune system to promote Treg induction, concomitant with decreased inflammation in 18	
the intestines158-160.  19	
The short chain fatty acid propionate is converted into glucose in the intestine, 20	
resulting in decreased glucose production from the liver161.  Propionate also acts as an 21	
agonist of FFAR3, inducing the peripheral nervous system to alter host metabolism by 22	
decreasing adiposity, body weight and glucose production in the liver, thus promoting 23	
better glucose control162.  In addition, SCFAs can regulate the expression of peptide YY 24	
(an enteroendocrine hormone) that controls gut motility and transit rate, as well as SCFA 25	
uptake and can promote anti-inflammatory properties, offering protection from induced 26	
inflammatory diseases such as colitis, arthritis and asthma in mouse models163, 164.  Thus, 27	
increased production of SCFAs from dietary fiber supplements or the ingestion of 28	
probiotics can inhibit pro-inflammatory cytokines and chemokines that could be used in 29	
potential treatments for autoimmunity e.g. colitis.  However, a balance would be 30	
	 18	
required, as SCFAs are an additional source of calories and can be associated with 1	
obesity and metabolic syndrome165.  2	
While less is known about the role of SCFAs in the development of T1D, a few 3	
recent studies have suggested that SCFAs can modulate T1D susceptibility.  One study 4	
showed that feeding NOD mice with acetylated or butyrated high-amylose maize starch 5	
diets increased their serum concentrations of acetate or butyrate and protected NOD mice 6	
from developing diabetes166.  Further, protection was enhanced if NOD mice were fed 7	
with a combination of both acetylated and butyrated diets.  Interestingly, NOD mice fed 8	
with the high acetate diet had reduced frequencies and numbers of islet autoantigen-9	
reactive T cells in the spleen and pancreatic lymph nodes (PLNs).  However, the 10	
protection in NOD mice fed with a high butyrate-containing diet was related to increased 11	
Treg number with enhanced suppressive functions166.  Another study demonstrated that 12	
butyrate could influence the secretion of cathelicidin-related antimicrobial peptide 13	
(CRAMP) by islets, with higher concentrations of CRAMP associated with protection 14	
from T1D development167.  CRAMP expression was shown to alter the islet 15	
microenvironment, by inducing tolerogenic islet macrophages, regulatory DCs and Tregs, 16	
all of which facilitate the reduction of autoreactive T cell activation and thus prevent 17	
diabetes development.  Altering the microbiota composition by fecal transfer or by 18	
antibiotic treatment can change the availability of metabolites, which in turn, alters the 19	
risk of developing T1D168, 169.  Therefore, these options may prove useful in developing 20	
prevention therapies.  However, the relationship between microbial metabolism and 21	
human T1D is still not well understood, and more studies in this area are needed in the 22	
future.   23	
 Diet and Type 1 Diabetes 24	
 Diet is well known to influence microbial composition and functions.  In Burkina 25	
Faso, Africa, where diets consist of an abundance of complex carbohydrates resulting in 26	
higher microbial diversity, children produce greater amounts of SCFAs when compared 27	
to children from Europe170.  In contrast, GF mice colonized with human stool bacteria 28	
from an individual with a Western-style diet had less microbial diversity and a worsened 29	
ability to metabolize complex carbohydrates.  However, those mice given the stool 30	
bacteria from the individuals with an enriched microbiota-accessible carbohydrate diet 31	
	 19	
had increased microbial diversity and were able to metabolize complex carbohydrates19, 1	
171.  Interestingly, numerous studies have suggested that Prevotella:Bacteroides ratios are 2	
related to the dietary intake of either complex carbohydrate diets or proteins and fats 3	
respectively170, 172.  Of note, when dietary fibers are almost completely fermented, the pH 4	
of the large intestine increases, providing a reduction in butyrate-producing microbiota 5	
but an increase in acetate- and proprionate-producing Bacteroides bacteria173. 6	
A barley kernel-based bread diet was introduced to healthy subjects for 3 days in a recent 7	
dietary intervention study174.  The authors identified the improvement of glucose 8	
metabolism to be associated with an increased abundance of Prevotella copri174.  The 9	
presence of Prevotella in these individuals had enhanced enzymatic activity related to 10	
breaking down complex carbohydrates, which promotes the generation of a number of 11	
SCFAs.  The colonization of GF mice with microbiota from the study participants also 12	
confirmed an increased abundance of Prevotella that was associated with improved 13	
glucose metabolism.  Furthermore, branched-chain fatty acid produced by the 14	
fermentation of branched-chain amino acids correlated with insulin resistance in germ-15	
free mice receiving stool bacteria from obese human individuals175. 16	
Dietary influence on T1D has been examined both as a causative agent as well as 17	
a preventative or modulating factor.  Oral administration of nicotinamide, a vitamin B 18	
group substance, to NOD mice prevented the development of diabetes176.   Further, NOD 19	
mice were completely protected from T1D development when administered nicotinamide 20	
in combination with a diet consisting of an infant formula, where soy was the source of 21	
protein177.  Vitamin D, specifically the active form, 1,25 di-hyroxyvitamin D, has also 22	
been shown to prevent from severe insulitis due to the increased Treg cell activity178-180.  23	
Gluten, a component of wheat protein, has many antigenic properties, and has been 24	
implicated in the pathogenesis of several autoimmune disease states (predominantly CD) 25	
but it has also been implicated in T1D.  It has been reported that CD can affect up to 26	
~10% of individuals with T1D due to the overlap in HLA-DR3/DQ2 genetic susceptibility 27	
between the two diseases181, 182.  Furthermore, tissue transglutaminase antibodies are 28	
present in some T1D patients, who share susceptibility SNPs to CD in the CTLA4 29	
gene183.  Even in those individuals with T1D who were negative for the tissue 30	
transglutaminase autoantibody in the serum, the antibody was still found in the 31	
	 20	
jejunum184.  Interestingly, T1D patients have increased expression of duodenal 1	
inflammatory chemokines and cytokines compared to CD patients and healthy controls32.  2	
This was also associated with altered microbiota in those T1D patients.  Gluten-free diets 3	
have been shown to protect NOD mice from the development of T1D185-187.  Two studies 4	
have shown that gluten in the diet affected the quantity and composition of the gut 5	
microbiota185, 186.  Funda and colleagues also reported that while a gluten-free diet 6	
prevented diabetes in NOD mice, a gluten-enriched diet also had a preventative 7	
effect187.  They hypothesized that gluten itself is not diabetogenic but can have an 8	
immunomodulatory effect on a diabetes-susceptible host by altering the gut microbiota 9	
which in turn regulates the immune system.   Human studies investigating how diet may 10	
influence T1D susceptibility are currently underway.  The BABYDIET study is a 11	
prospective primary prevention trial recruiting children “at risk” of developing diabetes, 12	
who have a first-degree relative with T1D and carry a T1D-risk HLA genotype.  Children 13	
were randomly assigned to one of two groups whereby gluten was introduced in the diet 14	
at 6 months or 1 year of age188.  Data from the participants within the first 3 years of age 15	
showed similar prevalence of islet autoimmunity regardless of when gluten was 16	
introduced; however, these children will continue to be followed over time, to observe 17	
generation of autoantibodies and other markers that are associated with the development 18	
of both celiac and T1D autoimmunity.   19	
 20	
 21	
Antibiotic usage and Type 1 Diabetes 22	
 23	
 There are many different classes of antibiotics that target different bacterial 24	
pathogens.  In addition to clearing the pathogen(s) from the original infection in various 25	
body sites, antibiotics can alter the gut microbiota directly, particularly as most of the 26	
antibiotics are taken via oral route.  Will antibiotic usage affect T1D development by 27	
changing gut microbiota?  Studies in mouse models of T1D suggest that the type of 28	
antibiotics, time of usage (early in life or later in life) and the duration of usage can 29	
modify the susceptibility of T1D development.  Table 1 summarizes different studies 30	
conducted to assess the role of microbial modulation in the development of T1D in NOD 31	
	 21	
mice.  We have shown that vancomycin, which predominantly targets Gram-positive 1	
bacteria, promoted T1D development in NOD mice, whereas neomycin, which targets 2	
Gram-negative bacteria, protected NOD mice from T1D development189, 190.  3	
Interestingly, others have reported that life-long vancomycin usage protected NOD mice 4	
from T1D development191.  It is clear that not all antibiotics have the same impact on 5	
T1D development.  Some antibiotics can protect NOD mice from the development of 6	
T1D189-191, while others promote the development of diabetes in NOD mice168, 192, 193.  7	
Interestingly, we found that the treatment of combination of four different antibiotics 8	
(ampicillin, vancomycin, metronidazole and neomycin, AVMN) had no effect on 9	
diabetes development in NOD mice despite the fact that the AVMN treatment depleted 10	
most, if not all, gut bacteria (Peng, et al., unpublished).  This highlights the observation 11	
that the treatment protocol can also influence diabetes development.  In the study 12	
showing that vancomycin protected NOD mice, the mice were treated from birth to 28 13	
days of age or from 8 weeks of age to termination191.  However, in the studies showing 14	
that vancomycin accelerated T1D development, NOD mice were treated from conception 15	
to termination or from conception to 24 hours post-birth190, 193.  The different treatment 16	
protocols, including dose, duration and starting age for these antibiotic studies make it 17	
difficult to compare the outcome of different studies directly.  Moreover, the gender of 18	
the mice used in the studies may also affect diabetes development.  As discussed earlier, 19	
sex hormones influence the gut microbiota and T1D susceptibility in the NOD mouse138, 20	
153.  While most studies have used female mice, some studies have been conducted in 21	
both genders.  Candon and co-authors found that long-term (from conception to the 22	
progeny at 40 wks of age) treatment with vancomycin or a combination of streptomycin, 23	
colistin and ampicillin (Strep-Col-Amp) significantly increased diabetes development in 24	
male NOD mice but had no effect on female mice193.  In another study, male NOD mice 25	
receiving tylosin also exhibited increased diabetes development168.  Interestingly, the 26	
female NOD mice, also exhibited increased diabetes development in one animal facility 27	
but this was not reproducible in a second animal facility.  This raises an important point 28	
that the resident gut microbiota and animal facility standards can influence the 29	
experimental outcome.  This also raises the issue of reproducibility of studies as small 30	
microbial changes may influence the effectiveness of the antibiotic treatment.  Clearly, 31	
	 22	
these studies are not possible in humans; however, epidemiological investigations into 1	
antibiotic usage and T1D development in humans have not shown any evidence that 2	
antibiotics administered to children have influenced the onset of T1D.  3	
 4	
Future Directions: Manipulating the gut microbiota as a novel therapy  5	
 6	
Probiotics 7	
Probiotics are microorganisms that may have health benefits by modifying the gut 8	
microbiota and improve nutrient absorption, enhance immune regulation and protect the 9	
host from infection and disease194.  While many of the probiotics may not colonize their 10	
hosts in the long-term, they do have important immunomodulatory effects in the short-11	
term195.   12	
Probiotics have been shown to protect NOD mice and BB rats from developing 13	
T1D196-199.  Lactobacillus casei, which is believed to be a probiotic strain, can protect 14	
NOD mice from T1D development when administered in the diet from 4 weeks of age196.  15	
This protection was associated with decreased splenic CD8 T cell number and increased 16	
IL-10 and IL-2 cytokines with age.  The probiotic VSL#3 is a mixture of bifidobacteria 17	
(B. longum, B. infantis and B. breve), lactobacilli (L. acidophilus, L.casei, L. delbrueckii 18	
subsp. L. bulgaricus and L. plantarum) and a strain of streptococcus bacteria 19	
(Streptococcus salivarius subsp. thermophilus)197.  In a study, Calcinaro and colleagues 20	
administered VSL#3 to NOD mice, three times per week from 4 to 32 weeks of age and 21	
this protocol led to significant protection from T1D development in treated NOD mice 22	
compared to non-treated controls (21% vs 81% respectively).  VSL#3 administration 23	
decreased expression of IL-1β and increased expression of indoleamine 2,3-dioxygenase 24	
and IL-33, both of which have tolerogenic properties199.  However, in another study, 25	
VSL#3 was administered via the drinking water to pregnant mice, just before birth until 26	
termination of the progeny (22 wks old), and this did not protect NOD mice from the 27	
development of T1D169.  In a very recent study, Hanninen and colleagues reported that 28	
Akkermansia muciniphila abundancy is negatively correlated to T1D development and 29	
oral transfer of A. muciniphila delays diabetes development in NOD/Jax mice that, 30	
otherwise, have an early disease onset200.  However, A. muciniphila did not reduce the 31	
	 23	
overall incidence of diabetes200, whereas gavage of Clostridium butyricum 1	
CGMCC0313.1 was able to significantly reduce the incidence of diabetes in NOD mice 2	
by promoting regulatory T cells201. 3	
There have been some studies investigating probiotics and host immunity in 4	
humans.  Treating CD children with two Bifidobacterium breve strains, Primec and co-5	
authors identified changes in microbiota composition that were associated with the 6	
changes in SCFAs and reduced TNFα in circulation202.  The authors also found that 7	
Verrucomicrobia, Parcibacteria and some other bacteria yet unknown phyla were 8	
strongly correlated to TNFα202.  The probiotic administration to the CD children lowered 9	
the level of TNFα and reduced the abundance of Verrucomicrobia202.  This may provide 10	
potential therapeutic targets for CD.  However, in a different disease setting, a reduced 11	
proportion of Verrucomicrobia has also been associated with glucose intolerance in type 12	
2 diabetes patients and prediabetes subjects203.  There have also been a few studies in 13	
T1D.  A double-blind randomized pilot study investigated how Lactobacillus johnsonii 14	
N6.2, which was shown to delay T1D onset in BB rats198, affects the host immunity in 15	
healthy adults204.  In this phase I human study, only healthy individuals without 16	
gastrointestinal disorders or other health issues (e.g. diabetes, mental diseases, kidney and 17	
heart diseases and others) were recruited for the study.  The administration of L. johnsonii 18	
N6.2 (taken in capsules for over 8 weeks) resulted in an increase of tryptophan in the 19	
circulation204.   It is known that tryptophan promotes Treg cell induction and expansion 20	
as well as suppresses the differentiation of Th1 cells.  These data suggest that L. johnsonii 21	
N6.2 is safe for treatment in adults, although the authors found that the study subjects had 22	
increased monocytes, NK cells and CD8 T cells in the peripheral blood compared to the 23	
placebo controls204.  It is clear that more studies need to be done before launching clinical 24	
trials in the subjects with T1D or those at risk of developing T1D.  25	
The Environmental Determinants of Diabetes in the Young (TEDDY) study 26	
follows children at risk of developing T1D to understand how different environmental 27	
factors may influence T1D susceptibility in humans.  Recent data from the TEDDY study 28	
have revealed a large variability in the fecal microbial probiotic (total lactobacilli and L. 29	
plantarum) compositions between the children, particularly before 10 months of age205.  30	
It is currently unknown whether those with a reduced abundance of lactobacilli in early 31	
	 24	
life will have a greater risk of developing T1D; however, the TEDDY study shows the 1	
presence of probiotic-related bacteria in children who are at risk of developing T1D, and 2	
correlating this with development of diabetes, over time, will be of considerable interest.  3	
This is an ever-expanding area with more probiotic-based human T1D clinical trials 4	
planned. 5	
 6	
Fecal Microbiota Transplantation 7	
 Fecal microbiota transplantation (FMT) can change the gut microbiota in the 8	
recipients to elicit health benefits.  FMT involves processing stool from a healthy donor 9	
(for allogeneic transplants) or from the recipient (autologous transplant), although more 10	
often the FMT is an allogeneic transplant from a healthy donor.  Sometimes the FMT 11	
recipients may need to be treated with antibiotics 24-72 hours prior to FMT to eliminate 12	
any existing deleterious gut microbiota.  An alternative approach to fast, and have bowel 13	
preparaton shortly before the treatment.  FMT has been used for the treatment of severe 14	
Clostridium difficile-induced colitis206.  Many studies confirmed that FMT therapy is safe 15	
and effective in treating human IBD207.  Interestingly, FMT (from lean donor feces) 16	
improves insulin sensitivity in individuals with metabolic syndrome208.   17	
 In T1D, promising results using FMT have been shown in mice.  Our study 18	
showed that fecal materials from MyD88-/-NOD mice, which were protected from 19	
diabetes, can delay and reduce diabetes development in NOD mouse recipients 209  20	
However, there has been no report to date on whether FMT could be beneficial in 21	
ameliorating disease in T1D patients or in preventing T1D development in the individuals 22	
who are at risk of developing T1D.  Both NOD mouse studies and recent TEDDY studies 23	
have pointed to early life as an important window of opportunity for effective 24	
intervention to reduce islet autoimmunity, especially in relation to the composition of gut 25	
microbiota56 and possibly FMT.   26	
 27	
Concluding remarks 28	
 29	
Increasing evidence suggests that there are microbial perturbations in individuals 30	
with islet autoimmunity or T1D compared to healthy control subjects; however, we are 31	
	 25	
still not clear about the defined mechanisms.  Therefore, further functional studies are 1	
needed, not only to probe the interaction of microbiota with immune system but also to 2	
identify the causal link(s) between the presence of certain gut bacteria and diabetogenic 3	
autoimmune responses.  Germ-free NOD mice will provide a valuable tool in deciphering 4	
the role of the microbiota in relation to the development of T1D, both in vitro, and more 5	
importantly, in vivo.  While GF mice are known to have a less mature immune system, 6	
particularly in relation to the gut-associated mucosal lymphoid tissue210, GF NOD mice, 7	
still develop T cell-mediated T1D71, 138, 153, 211.  Thus, using these GF NOD mice as 8	
recipients for human stool from diabetic donors and healthy control donors, allows us to 9	
understand how the microbiota may modulate the immune system in T1D in vivo.  10	
Studies in obesity and T2D have shown that human gut microbiota can improve glucose 11	
control and insulin resistance and thus manipulation of the microbiota may also be used 12	
to achieve better glycemic control in patients with T1D.   13	
Diet and probiotics may provide easier acceptance and compliance in participants 14	
for disease prevention and/or intervention and/or modulation of disease.  However, there 15	
are still some challenges e.g. in dietary interventions, the subjects have to be at the age of 16	
taking solid food.  As for the use of probiotics, the question remains as to how long the 17	
beneficial immunomodulatory effects induced by probiotic will last and if further doses 18	
are required.  Moreover, while FMT may alter the gut microbiota in the longer term, 19	
many of these studies pre-treat with antibiotics which provides a niche allowing newly 20	
introduced microbiota to colonize.  It is noteworthy that antibiotic treatment may lead to 21	
antibiotic resistance.  In addition, it is highly possible that FMT-induced microbiota 22	
changes can be modified by diet and other factors.  Therefore, for future therapy 23	
development, we require further understanding of 1) microbial community interactions as 24	
a complex ecosystem; 2) the interaction of host microbiome with intestinal micro-25	
environment including gut epithelial cells and specialized gut endocrine cells including 26	
Goblet cells and Paneth cells and 3) the interaction of gut microbiota with the host 27	
immune cells locally and systemically.  Furthermore, we also need to better define 28	
subgroups of patients, as increasing evidence suggests that T1D is not a homogenous 29	
disease condition.  If we can combine the information on microbiota with clinical data, to 30	
truly decipher the results by subgrouping patients based on resident microbiota 31	
	 26	
prevalence, c-peptide concentrations, autoantibody presence and type, as well as 1	
autoreactive T cell information, we will be able to design treatment with more precision.  2	
In summary, the role of microbiota in T1D is complex.  While there are associations with 3	
microbial composition changes at the time of seroconversion and changes associated with 4	
disease onset, it remains unclear if the microbiota play a causal role in human T1D 5	
development.  However, studies in NOD mice have shown that microbial antigens 6	
stimulated diabetogenic CD8 T cells and accelerated T1D development103, 212.  It is clear 7	
from mouse and human studies, the microbiota can induce both proinflammatory and 8	
anti-inflammatory changes of the immune system. 9	
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